8-K: Jushi Holdings Reports Mixed Q2 2025 Financials

Jushi Holdings Inc. announced its second quarter 2025 financial results, reporting sequential revenue growth and improved Adjusted EBITDA and net loss, alongside strategic retail expansion.

Summary

• Total revenue for Q2 2025 was $65.0 million, showing sequential growth from $63.8 million in Q1 2025 and a slight year-over-year increase from $64.6 million in Q2 2024.
• Net loss improved sequentially to $12.3 million in Q2 2025, compared to $17.0 million in Q1 2025, but worsened significantly from a $1.9 million net loss in Q2 2024.
• Adjusted EBITDA increased 39.6% quarter-over-quarter to $13.7 million, up from $9.8 million in Q1 2025, but decreased 5.3% year-over-year from $14.5 million in Q2 2024.
• Gross profit was $28.9 million with a gross profit margin of 44.5% in Q2 2025, an increase from $25.8 million (Q1 2025) but a decrease from $32.6 million (Q2 2024).
• Cash, cash equivalents, and restricted cash stood at $25.2 million as of June 30, 2025.
• The company received approximately $4.0 million in Employee Retention Credit (ERC) claims, including interest, with about $1 million representing incremental cash.
• Jushi-branded product sales accounted for 56% of total retail revenue in Q2 2025, consistent with prior quarters.
• The company ended Q2 2025 with 40 operating dispensaries in seven states, up from 35 in Q2 2024.
• Approximately $3 million in proceeds were generated from the sale of non-core assets in Nevada.

Sentiment

Score: 6

Explanation: The sentiment is cautiously positive. While the company reported significant sequential improvements in profitability metrics (net loss, Adjusted EBITDA) and is executing on its retail expansion strategy, year-over-year comparisons show declines in net income and Adjusted EBITDA, and the company continues to operate at a net loss with substantial debt. The strategic focus on high-return investments and new market entry provides a positive outlook, but sustained profitability remains a challenge.

Positives

• Sequential revenue growth to $65.0 million in Q2 2025 from $63.8 million in Q1 2025.
• Significant sequential improvement in net loss, reducing to $12.3 million from $17.0 million in Q1 2025.
• Adjusted EBITDA increased 39.6% quarter-over-quarter to $13.7 million.
• Retail expansion strategy is on track, with 40 stores nationwide and plans for four additional store openings by year-end 2025 or early 2026, including the first New Jersey dispensary.
• Strengthened balance sheet with approximately $4.0 million received from Employee Retention Credit (ERC) claims, including $1 million in incremental cash.
• Generated approximately $3.0 million from the sale of non-core assets in Nevada, streamlining the footprint.
• Enhanced product offering with the launch of 602 new SKUs and the new lifestyle brand 'Shayo'.
• Operational improvements in grower-processor network leading to stronger yields and greater efficiency.

Negatives

• Net loss significantly worsened year-over-year to $12.3 million in Q2 2025 from $1.9 million in Q2 2024.
• Adjusted EBITDA decreased 5.3% year-over-year to $13.7 million from $14.5 million in Q2 2024.
• Gross profit and gross profit margin decreased year-over-year to $28.9 million and 44.5% respectively, from $32.6 million and 50.4% in Q2 2024.
• Wholesale revenue decreased by $2.0 million year-over-year, primarily due to limited product availability for third-party sales in Virginia and a decline in bulk cannabis flower sales in Massachusetts.
• Ongoing competitive pricing pressure across various markets led to lower average selling prices despite higher unit sales.
• Increased operating expenses year-over-year due to amortization of business licenses and new dispensary openings.
• High total gross debt of $205.6 million long-term and $7.9 million short-term as of June 30, 2025.
• Negative net cash flows used in operations of $1.9 million in Q2 2025.

Risks

• Limited operating history of the industry and the Company.
• Risks related to managing the growth of the Company, including potential future impairment of goodwill or intangibles acquired and post-closing disputes from acquisitions or dispositions.
• Risks related to the continued performance, expansion, and/or optimization of existing operations in California, Illinois, Massachusetts, Nevada, Ohio, Pennsylvania, and Virginia.
• Risks related to the anticipated openings or relocation of additional dispensaries, which are subject to licensing approval.
• History of operating losses and negative operating cash flows.
• Increasing competition in the cannabis industry.
• Risks inherent in an agricultural business, such as the effects of natural disasters.
• Reliance on the expertise and judgment of senior management.
• Risks associated with cannabis products manufactured for human consumption, including potential product recalls.
• Limited research and data relating to cannabis.
• Constraints on marketing products.
• Risk of litigation.
• Insurance-related risks.
• Public opinion and perception of the cannabis industry.
• Risks related to the economy generally.
• Fraudulent activity by employees, contractors, and consultants.
• Risks relating to the Company's current amount of indebtedness.
• Reliance on key inputs, suppliers, skilled labor, and third-party service provider contracts.
• Reliance on manufacturers and contractors.
• Risks of supply shortages or supply chain disruptions.
• Risks relating to pandemics and forces of nature.
• Risks related to the enforceability of contracts.
• Risks related to inflation, the rising cost of capital, and stock market instability.
• Risks relating to the U.S. regulatory landscape and enforcement related to cannabis, including political risks.
• Risks relating to anti-money laundering laws and regulation.
• Cannabis-related tax risks and challenges from governmental authorities with respect to the Company's application for Employee Retention Tax Credits (ERC).
• Other governmental and environmental regulation.
• Risks related to proprietary intellectual property and potential infringement by third parties.
• Sales of a significant amount of shares by existing shareholders.
• The limited market for securities of the Company.
• Risks relating to the need to raise additional capital either through debt or equity financing.
• Costs associated with the Company being a publicly-traded company and a U.S. and Canadian filer.
• Risks related to co-investment with parties with different interests to the Company.
• Conflicts of interest and related party transactions.
• Cybersecurity risks.
• Risks related to the Company's critical accounting policies and estimates.
• Ability to continue as a going concern.

Future Outlook

The company expects to open its first New Jersey dispensary and a sixth Ohio location in late Q3 or early Q4 2025, with two additional locations planned for Q4 2025 or early Q1 2026, all pending regulatory approvals. Management is directing capital towards high-return investments in grower-processor operations to strengthen operational capabilities ahead of potential regulatory catalysts and market maturity, particularly in Pennsylvania and Virginia, while remaining open to opportunistic retail expansion. The focus remains on driving sustainable growth, expanding market reach, and delivering long-term shareholder value.

Management Comments

• "The topline growth we achieved this quarter both sequentially and year-over-year is an early but encouraging sign that our disciplined cost controls and targeted platform enhancements are taking hold."
• "This performance reinforces confidence in our strategic direction as we remain focused on driving profitability, expanding margins, and achieving continued sequential reductions in net loss."
• "Operational improvements across our grower-processor network are translating into stronger yields and greater efficiency, supported by the ongoing ramp-up of high-margin product lines."
• "During the second quarter, we also strengthened our balance sheet and streamlined our footprint with approximately $3 million in proceeds from the sale of non-core assets in Nevada. This reflects our broader strategy to concentrate our retail presence in the most profitable, high-potential markets."
• "Our retail expansion strategy remains firmly on track, with four new locations expected to open by year-end or early 2026 and a strong pipeline of additional opportunities."
• "Ohio has become an increasingly important market for us, driven by the recent addition of new stores. We are expanding our footprint and strengthening our position across both the retail and wholesale channels in the state."
• "Entering New Jersey represents a major milestone as our first new market in over two years and underscores our belief that the proven appeal of our brands in other markets will translate well into this new state."
• "Our robust retail footprint has always been a cornerstone of our growth strategy, and with that foundation in place, we are now directing capital toward high-return investments in our grower-processor operations."
• "While we remain open to opportunistic retail expansion beyond our current pipeline, this shift reflects a disciplined capital allocation strategy designed to strengthen our operational capabilities ahead of potential regulatory catalysts and broader market maturity, particularly in Pennsylvania and Virginia."
• "As we continue to bolster our platform, we remain focused on driving sustainable growth, expanding our market reach, and delivering long-term value for our shareholders."

Industry Context

Jushi Holdings Inc. operates as a vertically integrated, multi-state cannabis operator in the U.S. The company is navigating a competitive market characterized by pricing pressure, particularly impacting wholesale revenue. Its expansion into new adult-use markets like Ohio (which transitioned in Q3 2024) and the planned entry into New Jersey reflect a broader industry trend of operators seeking growth in newly legalized or expanding states. The focus on optimizing grower-processor operations and high-margin product lines aligns with industry efforts to improve profitability amidst evolving market dynamics.

Legal Proceedings

• The company lists 'risk of litigation' as a general factor that may cause actual results to differ materially.

Related Party Transactions

• Debt, net current portion includes related party principal amounts of $1.6 million as of June 30, 2025.
• Debt, net non-current includes related party principal amounts of $40.32 million as of June 30, 2025.

Stakeholder Impact

• Shareholders: The company aims to maximize shareholder value and deliver long-term value. Mixed financial results (sequential improvements vs. YOY declines) could impact investor sentiment.
• Employees: Receipt of Employee Retention Credit (ERC) claims benefits the company, potentially supporting employee retention.
• Customers: Enhanced product offerings (602 new SKUs, Shayo brand) and retail expansion (new stores, relocations) aim to improve customer access and choice.
• Suppliers: The company's reliance on key inputs and suppliers is a noted risk, indicating potential impact on supplier relationships if disruptions occur.
• Creditors: The company's significant debt levels and ongoing net losses are relevant to creditors, though sequential improvements in profitability metrics could be viewed positively.

Next Steps

• Host a conference call and audio webcast for Q2 2025 financial results on August 5, 2025.
• Open the first New Jersey dispensary in Little Ferry and a sixth Ohio location in Parma in late Q3 or early Q4 2025, pending regulatory approvals.
• Open two additional locations (one in New Jersey and one in Ohio) in Q4 2025 or early Q1 2026, subject to regulatory approval.
• Plan several store relocations to optimize retail performance by moving underperforming stores to higher performance locations.
• Direct capital toward high-return investments in grower-processor operations to strengthen operational capabilities.
• Continue to focus on driving sustainable growth, expanding market reach, and delivering long-term value for shareholders.

Key Dates

Recommendation

While Jushi Holdings Inc. demonstrated encouraging sequential improvements in revenue, net loss, and Adjusted EBITDA, and is actively pursuing strategic retail expansion into new markets like New Jersey, the year-over-year performance shows declines in key profitability metrics and the company continues to incur significant net losses. The substantial debt load and ongoing competitive pressures present headwinds. A 'hold' recommendation is warranted as investors should monitor the company's ability to sustain sequential improvements, successfully execute its expansion plans, and demonstrate a clear path to consistent profitability and positive cash flow from operations before considering a stronger position.

Keywords

Cannabis, Multi-State Operator, MSO, Dispensary, Retail Expansion, Financial Results, Q2 2025, Jushi Holdings, Marijuana, Adult-Use Cannabis, Medical Cannabis, Adjusted EBITDA, Revenue